Clinical trials: Temozolomide, completed
Solid Tumor
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
The purpose of this research study is to test the safety and of adding bevacizumab to the established regimen of vincristine, oral irinotecan, and temozolomide (VOIT) and see what effects it has in pediatric patients with…
- Trial name
- VITAC (NCT00786669)
- Testing
- Bevacizumab, Temozolomide, Vincristine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
This protocol will study treatment for Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumor (DSRCT). Participants with ESFT will be divided into two treatment groups, A or B, based on tumor…
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT01946529
- Testing
- vincristine, doxorubicin, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Melanoma
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
The purpose of this study is to ascertain if the extended schedule of Temozolomide, which allows increased doses and potential depletion of the enzyme underlaying resistance, is a more effective treatment of metastatic melanoma…
- Trial name
- NCT00091572
- Testing
- Temozolomide, Dacarbazine
- Volunteers
- 859 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain and Central Nervous System Tumors
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide, carmustine, and lomustine, use different ways to stop tumor cells from dividing so they stop growing or…
- Trial name
- NCT00004259
- Testing
- BCNU 80mg/m2, TMZ 200mg/m2, radiation therapy
- Where
- 92 sites in United States
- Volunteers
- 230 people
- Sponsor
- Radiation Therapy Oncology Group
Diarrhea, Drug/Agent Toxicity by Tissue/Organ
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
- Trial name
- NCT00093353
- Testing
- cefixime, irinotecan hydrochloride, temozolomide
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Brain and Central Nervous System Tumors
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005951
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- United States
- Sponsor
- Duke University
Glioblastoma Multiforme
Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients
The aim of this study is to establish FET-PET as an additional therapy assessment parameter in patients diagnosed with a glioblastoma multiforme receiving radiochemotherapy and adjuvant chemotherapy after previous resection or…
- Trial name
- NCT01089868
- Where
- 3 sites in Germany
- Volunteers
- 79 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Brain and Central Nervous System Tumors
Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004068
- Testing
- irinotecan hydrochloride, temozolomide, conventional surgery
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- St. Jude Children's Research Hospital
Malignant Glioma, Glioblastoma
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
This is a phase II study of the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and topotecan in grade IV malignant glioma patients.
- Conditions
- Malignant Glioma, Glioblastoma, Gliosarcoma
- Trial name
- NCT01004874
- Testing
- Bevacizumab, Temozolomide, Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Duke University
Neuroendocrine Tumors
Capecitabine and Temozolomide for Neuroendocrine Cancers
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET).
- Trial name
- NCT00869050
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Columbia University
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00498927
- Testing
- temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Soft Tissue Sarcoma
Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer
The purpose of this study is to determine whether treatment with temozolomide can effect the survival of patients with advanced breast cancer or soft tissue sarcoma.
- Trial name
- NCT00194766
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Chemo-radiation Induced Nausea and Vomiting
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
The purpose of this phase 2 study is to assess the efficacy and patient satisfaction of oral rolapitant plus ondansetron vs. oral ondansetron monotherapy in malignant glioma (MG) patients receiving standard of care radiation (RT)…
- Trial name
- NCT02991456
- Testing
- Rolapitant, Ondansetron
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Glioblastoma
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
This study is a phase I, open label trial to determine the Maximum Tolerated Dose (MTD), safety, pharmacokinetics, and efficacy of BIBW 2992 (an epidermal growth factor receptor(EGFR)inhibitor) to be used in combination with…
- Trial name
- NCT00977431
- Testing
- Temozolomide, Radiotherapy, BIBW2992
- Where
- 5 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Glioblastoma
Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide.
- Trial name
- NCT01907165
- Testing
- Temozolomide, Disulfiram, Copper gluconate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Glioblastoma Multiforme
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone.
- Trial name
- EF-32 (NCT04471844)
- Testing
- Optune®
- Where
- 130 sites in United States, Austria and 9 more
- Volunteers
- 981 people
- Sponsor
- NovoCure Ltd.
Glioma, Glioblastoma Multiforme
Temozolomide Chronotherapy for High Grade Glioma
Temozolomide (TMZ) is the chemotherapy drug approved by the FDA to increase survival in glioblastoma (GBM) patients beyond surgical resection and radiation therapy alone.
- Trial name
- NCT02781792
- Testing
- Temozolomide, Functional Assessment of Cancer Therapy - Brain, ActTrust Condor Instrument Watch
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Brain and Central Nervous System Tumors
Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01019434
- Testing
- temozolomide, temsirolimus
- Where
- 13 sites in Belgium, France and 6 more
- Volunteers
- 111 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ewing's Sarcoma (ES)
Protocol for the Treatment of Metastatic Ewing Sarcoma
Study for the treatment of metastatic Ewing sarcoma with high doses chemotherapy, radiotherapy and maintenance therapy.
- Trial name
- EW-2 (NCT02727387)
- Testing
- TEMIRI, ADM, IFO
- Where
- 13 sites in Italy
- Volunteers
- 155 people
- Sponsor
- Italian Sarcoma Group
Malignant Melanoma
A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy
This is the phase II, single-arm, single-center study assessing the efficacy of weekly docetaxel plus carboplatin in second-line treatment of malignant melanoma (unresectable or metastatic) who has failed dacarbazine or…
- Trial name
- NCT02223884
- Testing
- docetaxel 35mg/m2, Carboplatin AUC3
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University